For the quarter, the S&P 500® Index added 2.41%, while the MSCI EAFE Index slid 8.11%. Click here to read the full commentary ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Low bond yields and interest rates are often credited with supporting higher prices in the stock market. That's because lower bond yields can make the potentially higher yields offered by stocks ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of ...

Jones Financial Companies Lllp raised its stake in Sanofi (NASDAQ:SNY – Free Report) by 55.0% during the 4th quarter, ...

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related ...

Berenberg analyst Luisa Hector raised the firm’s price target on Sanofi (SNY) to EUR 120 from EUR 115 and keeps a Buy rating on the ...

With an average analyst rating of buy, Sanofi is clearly an analyst favorite. But the analysts could be wrong. Is SNY ...

He holds a BA from UC Santa Barbara and an MFA from The New School. Why are egg prices so high? A major bird flu outbreak has led to millions of hens being culled, causing a severe egg shortage.

Sanofi India share price gains were likely driven by its quarterly results performance and the dividend announcements, even though stock gave away most gains as the stock market crashed and Sensex ...

Sanofi Indias standalone net profit jumped 31% Rs 91.3 crore in Q4 FY25 as compared with Rs 69.7 crore in Q4 FY24. Revenue increased 9.7% YoY to Rs 514.9 crore in Q4 FY25. Schaeffler Indias ...

Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the ...